Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;54(10):1575-1585.
doi: 10.1038/s41409-019-0465-9. Epub 2019 Feb 6.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Jakob R Passweg  1 , Helen Baldomero  2 , Grzegorz W Basak  3 , Christian Chabannon  4 , Selim Corbacioglu  5 , Rafael Duarte  6 , Jürgen Kuball  7 , Arjan Lankester  8 , Silvia Montoto  9 , Régis Peffault de Latour  10 , John A Snowden  11 , Jan Styczynski  12 , Ibrahim Yakoub-Agha  13 , Mutlu Arat  14 , Mohamad Mohty  15 , Nicolaus Kröger  16 ; European Society for Blood and Marrow Transplantation (EBMT)
Affiliations

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Jakob R Passweg et al. Bone Marrow Transplant. 2019 Oct.

Abstract

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Relative proportion of disease indications for hematopoietic cell transplantation (HCT) in Europe between the years 1997, 2007, and 2017. a Relative proportion of allogeneic HCT. b Relative proportion of autologous HCT
Fig. 2
Fig. 2
Trends in the absolute numbers of allogeneic hematopoietic cell transplantation (HCT) for nonmalignant disorders in Europe 1990–2017
Fig. 3
Fig. 3
Changes in donor choice and stem cell source for bone marrow failure in Europe 1990–2017. a Donor choice. b Human leukocyte antigen identical sibling hematopoietic cell transplantation (HCT) by bone marrow (BM) or peripheral blood (PB). c Unrelated HCT by BM or PB. d Haploidentical HCT by BM or PB
See this image and copyright information in PMC

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. doi: 10.1056/NEJMra052638. - DOI - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–5. doi: 10.1056/NEJMp078166. - DOI - PubMed
    1. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–56. doi: 10.1038/bmt.2015.6. - DOI - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed
    1. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;ume 2(No. 3):e91–100. doi: 10.1016/S2352-3026(15)00028-9. - DOI - PubMed

Publication types